Objectives: To compare the efficacy and tolerability of allopurinol 300–600 mg/day versus
benzbromarone 100–200 mg/day used to attain a target serum urate concentration (sUr)⩽ …

We tested 16 million SNPs, identified through whole-genome sequencing of 457 Icelanders,
for association with gout and serum uric acid levels. Genotypes were imputed into 41,675 …

Background Allopurinol, a xanthine oxidase inhibitor, is considered one of the most effective
urate‐lowering drugs and is frequently used in the treatment of chronic gout. Objectives To …

Background Gout is an inflammatory arthritis that is characterised by the deposition of
monosodium urate crystals in synovial fluid and other tissues. The natural history of articular …

OBJECTIVE: Streamlining the initiation of allopurinol could result in a cost benefit for a
common medical problem and obviate the perception that no treatment is required once …

Objectives: To investigate the efficacy and tolerability of allopurinol as the first-choice
antihyperuricaemic treatment for gout, and compare the efficacy and tolerability of …

Background: Two recent double-blind, randomized, controlled trials (RCTs) showed that oral
steroids and nonsteroidal anti-inflammatory drugs have similar analgesic effectiveness for …

Acute gout attacks and the long-term complications of gout are associated with the
deposition of monosodium urate (MSU) monohydrate crystals in the joints and soft tissues …

Objective. The central strategy for effective gout management is longterm urate-lowering
therapy to maintain the serum urate at a level below 0.36 mmol/l. We sought to determine …

Objective Gout is associated with a higher risk of fracture; however, findings on the
associations of hyperuricemia and urate‐lowering therapy (ULT) with the risk of fracture …